

Andreas Ranft

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9300096/publications.pdf>

Version: 2024-02-01

69
papers

2,251
citations

257450

24
h-index

223800

46
g-index

75
all docs

75
docs citations

75
times ranked

2687
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 2307-2320. | 1.6 | 24 |
| 2 | Value of adjuvant radiotherapy in patients with localized Ewing sarcoma at the extremities: Report from the Ewing 2008 trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 11531-11531. | 1.6 | 0 |
| 3 | Pain in survivors of Ewing sarcoma: Prevalence, associated factors and prediction of recurrence. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28801. | 1.5 | 1 |
| 4 | Communication and ethical considerations for fertility preservation for patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. <i>Lancet Oncology</i> , The, 2021, 22, e68-e80. | 10.7 | 37 |
| 5 | Association of treatment delays with an unfavorable outcome in patients with localized Ewing sarcoma: A retrospective analysis of data from the GPOH Euro-E.W.I.N.G.99 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11502-11502. | 1.6 | 3 |
| 6 | Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma. <i>Molecular Cancer</i> , 2021, 20, 97. | 19.2 | 24 |
| 7 | Quantification of Translocation-Specific ctDNA Provides an Integrating Parameter for Early Assessment of Treatment Response and Risk Stratification in Ewing Sarcoma. <i>Clinical Cancer Research</i> , 2021, 27, 5922-5930. | 7.0 | 14 |
| 8 | Therapeutic targeting of the PLK1-PRC1-axis triggers cell death in genomically silent childhood cancer. <i>Nature Communications</i> , 2021, 12, 5356. | 12.8 | 11 |
| 9 | Stenotrophomonas maltophilia Infections in Pediatric Patients – Experience at a European Center for Pediatric Hematology and Oncology. <i>Frontiers in Oncology</i> , 2021, 11, 752037. | 2.8 | 10 |
| 10 | Which Factors Are Associated with Local Control and Survival of Patients with Localized Pelvic Ewing’s Sarcoma? A Retrospective Analysis of Data from the Euro-EWING99 Trial. <i>Clinical Orthopaedics and Related Research</i> , 2020, 478, 290-302. | 1.5 | 45 |
| 11 | Dynamic prediction of overall survival: a retrospective analysis on 979 patients with Ewing sarcoma from the German registry. <i>BMJ Open</i> , 2020, 10, e036376. | 1.9 | 0 |
| 12 | Fertility education for adolescent cancer patients: Gaps in current clinical practice in Europe. <i>European Journal of Cancer Care</i> , 2020, 29, e13279. | 1.5 | 5 |
| 13 | Primary and Metastatic Intracranial Ewing Sarcoma at Diagnosis: Retrospective International Study and Systematic Review. <i>Cancers</i> , 2020, 12, 1675. | 3.7 | 8 |
| 14 | Efficacy of add-on treosulfan and melphalan high-dose therapy in patients with high-risk metastatic Ewing sarcoma: Report from the International Ewing 2008R3 trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11501-11501. | 1.6 | 6 |
| 15 | Efficacy of maintenance therapy with zoledronic acid in patients with localized Ewing sarcoma: Report from the international Ewing 2008 trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11523-11523. | 1.6 | 8 |
| 16 | Individual risk evaluation for local recurrence and distant metastasis in Ewing sarcoma: A multistate model. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27943. | 1.5 | 17 |
| 17 | Easy-to-use clinical tool for survival estimation in Ewing sarcoma at diagnosis and after surgery. <i>Scientific Reports</i> , 2019, 9, 11000. | 3.3 | 13 |
| 18 | Gene expression and immunohistochemical analyses identify SOX2 as major risk factor for overall survival and relapse in Ewing sarcoma patients. <i>EBioMedicine</i> , 2019, 47, 156-162. | 6.1 | 23 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008. <i>Journal of Clinical Oncology</i> , 2019, 37, 3192-3202. | 1.6 | 84 |
| 20 | The relation of radiological tumor volume response to histological response and outcome in patients with localized Ewing Sarcoma. <i>Cancer Medicine</i> , 2019, 8, 1086-1094. | 2.8 | 14 |
| 21 | Recurrence of Ewing sarcoma: Is detection by imaging follow-up protocol associated with survival advantage?. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27011. | 1.5 | 22 |
| 22 | Survival is influenced by approaches to local treatment of Ewing sarcoma within an international randomised controlled trial: analysis of EICESS-92. <i>Clinical Sarcoma Research</i> , 2018, 8, 6. | 2.3 | 19 |
| 23 | Array-based DNA-methylation profiling in sarcomas with small blue round cell histology provides valuable diagnostic information. <i>Modern Pathology</i> , 2018, 31, 1246-1256. | 5.5 | 76 |
| 24 | High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008. <i>Journal of Clinical Oncology</i> , 2018, 36, 3110-3119. | 1.6 | 107 |
| 25 | Genetic variation in gonadal impairment in female survivors of childhood cancer: a PanCareLIFE study protocol. <i>BMC Cancer</i> , 2018, 18, 930. | 2.6 | 13 |
| 26 | PanCareLIFE: The scientific basis for a European project to improve long-term care regarding fertility, ototoxicity and health-related quality of life after cancer occurring among children and adolescents. <i>European Journal of Cancer</i> , 2018, 103, 227-237. | 2.8 | 41 |
| 27 | Impact of Whole Lung Irradiation on Survival Outcome in Patients With Lung Relapsed Ewing Sarcoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 584-592. | 0.8 | 16 |
| 28 | Impact of the Interdisciplinary Tumor Board of the Cooperative Ewing Sarcoma Study Group on local therapy and overall survival of Ewing sarcoma patients after induction therapy. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27384. | 1.5 | 22 |
| 29 | Age dependency of primary tumor sites and metastases in patients with Ewing sarcoma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27251. | 1.5 | 30 |
| 30 | T cell infiltration into Ewing sarcomas is associated with local expression of immune-inhibitory HLA-G. <i>Oncotarget</i> , 2018, 9, 6536-6549. | 1.8 | 37 |
| 31 | Results for patients with sarcoma not otherwise specified and other diagnoses than Ewing sarcoma treated according to the Euro-€EWING 99 trial. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26524. | 1.5 | 4 |
| 32 | Ewing sarcoma partial regression without GvHD by chondromodulin-I/HLA-A*02:01-specific allorestricted T cell receptor transgenic T cells. <i>Oncoimmunology</i> , 2017, 6, e1312239. | 4.6 | 21 |
| 33 | Ewing sarcoma during follow-up. <i>Nuklearmedizin - NuclearMedicine</i> , 2017, 56, 233-238. | 0.7 | 4 |
| 34 | Quality of Survivorship in a Rare Disease: Clinicofunctional Outcome and Physical Activity in an Observational Cohort Study of 618 Long-Term Survivors of Ewing Sarcoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 1704-1712. | 1.6 | 33 |
| 35 | Long-term outcome of patients with lower extremity Ewing sarcoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 117-117. | 1.6 | 0 |
| 36 | Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity. <i>Sarcoma</i> , 2016, 2016, 1-6. | 1.3 | 16 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Management and Outcome of Ewing Sarcoma of the Head and Neck. Pediatric Blood and Cancer, 2016, 63, 604-610. | 1.5 | 53 |
| 38 | Efficacy of busulfan-melphalan high dose chemotherapy consolidation (BuMel) in localized high-risk Ewing sarcoma (ES): Results of EURO-EWING 99-R2 randomized trial (EE99R2Loc).. Journal of Clinical Oncology, 2016, 34, 11000-11000. | 1.6 | 10 |
| 39 | Prognostic factors for local control in Ewing sarcoma (ES) in the Euro-EWING99 trial.. Journal of Clinical Oncology, 2016, 34, 11026-11026. | 1.6 | 2 |
| 40 | Gene expression profiling of <sc>E</sc>wing sarcoma tumours reveals the prognostic importance of tumourâ€stromal interactions: a report from the <sc>C</sc>hildren's <sc>O</sc>ncology <sc>G</sc>roup. Journal of Pathology: Clinical Research, 2015, 1, 83-94. | 3.0 | 66 |
| 41 | Local Control in Ewing Sarcoma of the Chest Wall: Results of the EURO-EWING 99 Trial. Annals of Surgical Oncology, 2015, 22, 2853-2859. | 1.5 | 39 |
| 42 | Development of Curative Therapies for Ewing Sarcomas by Interdisciplinary Cooperative Groups in Europe. Klinische Padiatrie, 2015, 227, 108-115. | 0.6 | 9 |
| 43 | Functional and clinical long-term outcome of Ewing sarcoma treatment*.. Journal of Clinical Oncology, 2015, 33, 10529-10529. | 1.6 | 0 |
| 44 | Abstract 458: Immune-inhibitory HLA-G is expressed in the tumor microenvironment of Ewing Sarcomas. , 2015, , . | | 0 |
| 45 | Differentially Expressed miRNAs in Ewing Sarcoma Compared to Mesenchymal Stem Cells: Low miR-31 Expression with Effects on Proliferation and Invasion. PLoS ONE, 2014, 9, e93067. | 2.5 | 34 |
| 46 | The value of highâ€dose chemotherapy in patients with first relapsed Ewing sarcoma. Pediatric Blood and Cancer, 2014, 61, 1382-1386. | 1.5 | 52 |
| 47 | Cyclophosphamide Compared With Ifosfamide in Consolidation Treatment of Standard-Risk Ewing Sarcoma: Results of the Randomized Noninferiority Euro-EWING99-R1 Trial. Journal of Clinical Oncology, 2014, 32, 2440-2448. | 1.6 | 136 |
| 48 | Long-term follow-up of the CESS 81 and CESS 86 Ewing sarcoma trials.. Journal of Clinical Oncology, 2014, 32, 10529-10529. | 1.6 | 0 |
| 49 | Abstract A72: Do prognostic gene signatures exist in Ewing sarcoma? A report from the Children's Oncology Group. , 2014, , . | | 0 |
| 50 | Renal Ewing tumors. Annals of Oncology, 2013, 24, 2455-2461. | 1.2 | 35 |
| 51 | Impact of gender on efficacy and acute toxicity in standard risk localized (SR) Ewing sarcomas (ES) in the Euro-Ewing99-R1 trial.. Journal of Clinical Oncology, 2013, 31, 10031-10031. | 1.6 | 1 |
| 52 | High STEAP1 expression is associated with improved outcome of Ewing's sarcoma patients. Annals of Oncology, 2012, 23, 2185-2190. | 1.2 | 43 |
| 53 | Ewing Sarcoma of the Hand or Foot. Klinische Padiatrie, 2012, 224, 348-352. | 0.6 | 7 |
| 54 | Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatric Blood and Cancer, 2011, 57, 549-553. | 1.5 | 228 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES). Cancer, 2010, 116, 443-450. | 4.1 | 137 |
| 56 | Impact of <i>EWS-ETS</i> Fusion Type on Disease Progression in Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumor: Prospective Results From the Cooperative Euro-E.W.I.N.G. 99 Trial. Journal of Clinical Oncology, 2010, 28, 1982-1988. | 1.6 | 180 |
| 57 | Ewing sarcoma of the head and neck.. Journal of Clinical Oncology, 2010, 28, e20516-e20516. | 1.6 | 1 |
| 58 | A high proportion of bone marrow T cells with regulatory phenotype (CD4+CD25 ^{hi} FoxP3+) in Ewing sarcoma patients is associated with metastatic disease. International Journal of Cancer, 2009, 125, 879-886. | 5.1 | 51 |
| 59 | Radiation Toxicity Following Busulfan/Melphalan High-dose Chemotherapy in the EURO-EWING-99-trial: Review of GPOH Data. Strahlentherapie Und Onkologie, 2009, 185, 21-22. | 2.0 | 32 |
| 60 | Treosulfan-based high-dose chemotherapy with autologous stem cell transplantation in high-risk Ewing sarcoma. Journal of Clinical Oncology, 2009, 27, 10546-10546. | 1.6 | 4 |
| 61 | Whole Lung Irradiation in Patients with Exclusively Pulmonary Metastases of Ewing Tumors. Strahlentherapie Und Onkologie, 2008, 184, 193-197. | 2.0 | 72 |
| 62 | Ewing tumors in infants. Pediatric Blood and Cancer, 2008, 50, 761-764. | 1.5 | 20 |
| 63 | Ewing's Tumors over the Age of 40 – a Retrospective Analysis of 47 Patients Treated According to the International Clinical Trials EICESS 92 and EURO-E.W.I.N.G. 99. Oncology Research and Treatment, 2008, 31, 657-663. | 1.2 | 22 |
| 64 | Treatment evolution in localized Ewing tumors of the pelvis and femur. Journal of Clinical Oncology, 2008, 26, 10513-10513. | 1.6 | 0 |
| 65 | Ewing tumours: Outcome in children, adolescents and adult patients. European Journal of Cancer, Supplement, 2007, 5, 209-215. | 2.2 | 6 |
| 66 | Microsatellite instability in Ewing tumor is not associated with loss of mismatch repair protein expression. Journal of Cancer Research and Clinical Oncology, 2007, 133, 749-759. | 2.5 | 22 |
| 67 | Risks of recurrence and survival after relapse in patients with Ewing tumor. Journal of Clinical Oncology, 2007, 25, 10012-10012. | 1.6 | 2 |
| 68 | Bone Marrow T Cell Subpopulations in Patients with Newly Diagnosed B-Cell Precursor Acute Lymphoblastic Leukemia (ALL).. Blood, 2007, 110, 4278-4278. | 1.4 | 7 |
| 69 | Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatric Blood and Cancer, 2006, 47, 795-800. | 1.5 | 148 |